UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20660) 20660
Magazine Article (174) 174
Dissertation (20) 20
Book / eBook (13) 13
Newsletter (5) 5
Web Resource (4) 4
Book Chapter (3) 3
Conference Proceeding (3) 3
Government Document (2) 2
Book Review (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15644) 15644
science & technology (14771) 14771
life sciences & biomedicine (14470) 14470
male (11458) 11458
female (8672) 8672
antidepressive agents - therapeutic use (7923) 7923
psychiatry (6734) 6734
animals (6510) 6510
adult (6215) 6215
antidepressants (5729) 5729
pharmacology & pharmacy (5306) 5306
middle aged (5113) 5113
neurosciences & neurology (4944) 4944
antidepressive agents - pharmacology (4448) 4448
antidepressive agents - administration & dosage (4439) 4439
neurosciences (4257) 4257
treatment outcome (3523) 3523
depression (3510) 3510
depression - drug therapy (3425) 3425
depressive disorder - drug therapy (3349) 3349
aged (3222) 3222
rats (3141) 3141
antidepressive agents - adverse effects (2910) 2910
depression, mental (2544) 2544
depressive disorder, major - drug therapy (2502) 2502
dose-response relationship, drug (2357) 2357
clinical neurology (2229) 2229
adolescent (2176) 2176
mice (2133) 2133
mental depression (1953) 1953
drug therapy (1783) 1783
drug therapy, combination (1741) 1741
time factors (1679) 1679
abridged index medicus (1618) 1618
analysis (1537) 1537
antidepressant (1522) 1522
double-blind method (1504) 1504
disease models, animal (1501) 1501
antidepressive agents, second-generation - therapeutic use (1500) 1500
drug administration schedule (1459) 1459
psychiatric status rating scales (1406) 1406
antidepressive agents, tricyclic - therapeutic use (1399) 1399
serotonin uptake inhibitors - therapeutic use (1382) 1382
research (1332) 1332
care and treatment (1315) 1315
behavior, animal - drug effects (1309) 1309
social sciences (1276) 1276
risk factors (1259) 1259
psychology (1241) 1241
rats, sprague-dawley (1205) 1205
antidepressive agents, tricyclic - administration & dosage (1198) 1198
antidepressive agents, second-generation - administration & dosage (1154) 1154
depressive disorder - psychology (1137) 1137
young adult (1132) 1132
general & internal medicine (1101) 1101
dosage and administration (1093) 1093
motor activity - drug effects (1089) 1089
drug interactions (1077) 1077
serotonin (1077) 1077
medicine, general & internal (1053) 1053
rats, wistar (1049) 1049
brain - drug effects (1001) 1001
antidepressive agents, second-generation - adverse effects (1000) 1000
major depressive disorder (960) 960
antidepressive agents, tricyclic - pharmacology (959) 959
fluoxetine (934) 934
child (933) 933
health aspects (925) 925
medicine & public health (905) 905
antipsychotic agents - therapeutic use (899) 899
brain - metabolism (868) 868
serotonin uptake inhibitors - adverse effects (853) 853
hippocampus - drug effects (852) 852
bipolar disorder - drug therapy (819) 819
clinical trials (808) 808
united states (803) 803
neurology (800) 800
drugs (785) 785
antidepressive agents, tricyclic - adverse effects (762) 762
aged, 80 and over (757) 757
anxiety (754) 754
swimming (747) 747
psychotherapy (742) 742
internal medicine (741) 741
comorbidity (738) 738
fluoxetine - pharmacology (734) 734
serotonin uptake inhibitors - administration & dosage (733) 733
antidepressive agents, second-generation - pharmacology (732) 732
severity of illness index (721) 721
depressive disorder, major - psychology (707) 707
randomized controlled trials as topic (706) 706
follow-up studies (695) 695
antidepressive agents (686) 686
serotonin - metabolism (683) 683
combined modality therapy (675) 675
depressive disorder - diagnosis (668) 668
pharmacology (668) 668
pharmacology/toxicology (665) 665
psychopharmacology (659) 659
depression - psychology (652) 652
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19626) 19626
German (379) 379
French (298) 298
Russian (234) 234
Japanese (184) 184
Spanish (79) 79
Norwegian (71) 71
Polish (69) 69
Swedish (63) 63
Portuguese (57) 57
Italian (47) 47
Hungarian (41) 41
Chinese (40) 40
Danish (40) 40
Dutch (29) 29
Turkish (18) 18
Finnish (11) 11
Czech (10) 10
Bulgarian (6) 6
Hebrew (6) 6
Lithuanian (4) 4
Ukrainian (4) 4
Serbian (2) 2
Afrikaans (1) 1
Greek (1) 1
Korean (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular psychiatry, ISSN 1476-5578, 02/2006, Volume 11, Issue 7, pp. 680 - 684
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E-2 ( PGE(2)), have repeatedly been... 
COX-2 inhibition | Inflammation | Psychoneuroimmunology | Major depression | Immunity | Biochemistry & Molecular Biology | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Anti-Anxiety Agents - administration & dosage | Dinoprostone - analysis | Pyrazoles - therapeutic use | Adrenergic Uptake Inhibitors | Dinoprostone - biosynthesis | Humans | Middle Aged | Depressive Disorder - drug therapy | Male | Patient Dropouts | Lorazepam - therapeutic use | Inflammation - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Antidepressive Agents - pharmacology | Anti-Anxiety Agents - therapeutic use | Drug Therapy, Combination | Morpholines - therapeutic use | Pyrazoles - pharmacology | Severity of Illness Index | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Cyclooxygenase 2 Inhibitors - administration & dosage | Morpholines - administration & dosage | Lorazepam - administration & dosage | Celecoxib | Sulfonamides - pharmacology | Antidepressive Agents - therapeutic use | Pilot Projects | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Depressive Disorder - physiopathology | Serotonin - metabolism | Interleukin-6 - biosynthesis | Antidepressive Agents - administration & dosage | Psychological Tests | Sulfonamides - administration & dosage | Inflammation - physiopathology | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus | Index Medicus
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 01/2005, Volume 97, Issue 1, pp. 30 - 39
Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Cytochrome P-450 CYP2C9 | Cytochrome P-450 CYP2D6 Inhibitors | Prospective Studies | Cytochrome P-450 CYP3A | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Antidepressive Agents, Second-Generation - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - metabolism | Breast Neoplasms - metabolism | Breast Neoplasms - enzymology | Cyclohexanols - metabolism | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Serotonin Uptake Inhibitors - metabolism | Tamoxifen - metabolism | Cytochrome P-450 CYP2D6 - genetics | Drug Administration Schedule | Enzyme Inhibitors - metabolism | Estrogen Receptor Modulators - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Tamoxifen - blood | Genotype | Arylsulfotransferase - genetics | Estrogen Receptor Modulators - blood | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Venlafaxine Hydrochloride | Serotonin Uptake Inhibitors - administration & dosage | Cytochrome P-450 Enzyme System - genetics | Aged | Estrogen Receptor Modulators - metabolism | Antidepressive Agents, Second-Generation - metabolism | Breast cancer | Dosage and administration | Drug therapy | Tamoxifen | Antidepressants | Side effects | Metabolism | Index Medicus
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 10/2009, Volume 166, Issue 10, pp. 1178 - 1184
Journal Article
The Lancet (British edition), ISSN 0140-6736, 08/2016, Volume 388, Issue 10047, pp. 881 - 890
... of prescription has increased over time. However, in 2004, the US Food and Drug Administration (FDA) cautioned practitioners on the use of antidepressants in children... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Mianserin - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Citalopram - adverse effects | Sertraline - adverse effects | Venlafaxine Hydrochloride - adverse effects | Imipramine - administration & dosage | Paroxetine - adverse effects | Mianserin - analogs & derivatives | Paroxetine - administration & dosage | Desipramine - adverse effects | Nortriptyline - administration & dosage | Nortriptyline - adverse effects | Mianserin - administration & dosage | Child | Fluoxetine - adverse effects | Depressive Disorder, Major - drug therapy | Clomipramine - administration & dosage | Duloxetine Hydrochloride - adverse effects | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Clomipramine - adverse effects | Evidence-Based Medicine | Desipramine - administration & dosage | Randomized Controlled Trials as Topic | Venlafaxine Hydrochloride - administration & dosage | Citalopram - administration & dosage | Confounding Factors (Epidemiology) | Sertraline - administration & dosage | Adolescent | Amitriptyline - adverse effects | Bayes Theorem | Fluoxetine - administration & dosage | Duloxetine Hydrochloride - administration & dosage | Antidepressive Agents - administration & dosage | Antidepressive Agents - adverse effects | Research Design | Amitriptyline - administration & dosage | Imipramine - adverse effects | Psychological aspects | Medical colleges | Neurosciences | Drugs and youth | Rankings | Comparative analysis | Child psychopathology | Major depressive disorder | Antidepressants, Tricyclic | Pediatric pharmacology | Mental illness | Studies | Teenagers | Mental depression | Antidepressants | Meta-analysis | Children & youth | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 1740-634X, 08/2010, Volume 35, Issue 12, pp. 2378 - 2391
.... To address this issue, we determined the influence of peripheral BDNF administration on depression-and anxiety-like behavior, including the forced swim test (FST... 
neurogenesis | dentate gyrus | depression | serum | neurotrophic factor | antidepressant | Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Anti-Anxiety Agents - metabolism | Recombinant Proteins - therapeutic use | Male | Anxiety - drug therapy | Extracellular Signal-Regulated MAP Kinases - metabolism | Hippocampus - drug effects | Antidepressive Agents - metabolism | Corpus Striatum - metabolism | Depression - drug therapy | Brain-Derived Neurotrophic Factor - pharmacology | Antidepressive Agents - pharmacology | Brain-Derived Neurotrophic Factor - metabolism | Neurogenesis - drug effects | Anti-Anxiety Agents - therapeutic use | Brain-Derived Neurotrophic Factor - therapeutic use | Disease Models, Animal | Recombinant Proteins - metabolism | Mice, Inbred C57BL | Anti-Anxiety Agents - pharmacology | Recombinant Proteins - pharmacology | Recombinant Proteins - administration & dosage | Infusions, Subcutaneous | Antidepressive Agents - therapeutic use | Brain-Derived Neurotrophic Factor - administration & dosage | Hippocampus - metabolism | Animals | Cyclic AMP Response Element-Binding Protein - metabolism | Corpus Striatum - drug effects | Mice | Mice, Inbred BALB C | Index Medicus | biological psychiatry | animal models | bipolar | unipolar | molecular and cellular neurobiology | Original
Journal Article